Impact of Antiplatelet Therapy and Platelet Reactivity Testing on Cardiovascular Outcomes in Patients with Chronic Kidney Disease

Sandeep Nathan,Brian Conway

DOI: https://doi.org/10.1007/978-3-319-56042-7_29

2017-01-01

Abstract:Chronic kidney disease (CKD) defined as GFR < 60 mL/min/1.73 m2 for ≥ 3 months, affects a significant proportion of the United States population and impacts, among other biologic processes, platelet-mediated hemostasis and thrombosis. The paradoxical predilection for both bleeding and ischemic complications, often in the same patient, complicates decisions regarding anticoagulant and antiplatelet therapies. The majority of cardiovascular research trials have excluded patients with moderate to severe CKD despite the wide acknowledgement that these patients are at high risk for adverse cardiovascular outcomes. The currently available oral antiplatelet agents (aspirin, clopidogrel, prasugrel, and ticagrelor) do not require adjustment for renal dysfunction, but vary greatly on the basis of potency, approved indications, and efficacy data in CKD. Available data suggests that aspirin monotherapy may be most appropriate for secondary prevention of cardiovascular events and is associated with an increase in minor bleeding. Dual antiplatelet therapy (DAPT) with aspirin and clopidogrel remains of uncertain value for secondary cardiovascular prevention in CKD patients and is not recommended for primary prevention. Dual antiplatelet therapy with prasugrel or ticagrelor, in addition to aspirin has shown promise but must be prospectively validated in appropriately sized outcomes studies. Inadequate pharmacodynamic response to oral antiplatelet therapy occurs in a significant proportion of CKD patients and has been associated with an increased risk of cardiovascular events (versus similar patients who evidence an acceptable antiplatelet response). Multiple approaches have been developed to estimate de novo platelet function and gauge residual platelet reactivity on antiplatelet therapy. These techniques vary greatly in methodology, sample preparation and resource utilization, but may be broadly divided into laboratory-based versus point-of-care testing. Platelet reactivity testing for the purposes of adjusting antiplatelet therapy in the individual patient remains a potential avenue for balancing the risks of bleeding and atherothrombotic events, however further study is required in the CKD population.